bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract A52: A pilot study to examine patient awareness and provider discussion of the impact of cancer treatment on fertility in a registry-based sample of African American women with breast cancer
Authors: Christie Juliette , Pal Tuya , Quinn Gwendolyn , Fleming Patrice , Stowe Caitlin , Bower Bethanne , Vadaparampil Susan 
Published: June 2012

Abstract
Introduction: Although African American (AA) women are more likely to be diagnosed with early onset breast cancer (i.e., ≤ age 50) during their reproductive years, little is known about patient awareness of or provider discussion related to fertility concerns in this specific demographic group. In an effort to better understand how fertility concerns are addressed in the context of clinical care, this study seeks to document the prevalence of patient awareness and patientprovider discussion of infertility risk associated with cancer treatment in AA breast cancer patients.
Method: As part of a larger study examining the role of genetic factors in AA women with early onset breast cancer, data were collected using a cross-sectional survey. Demographic and clinical variables were compared using chisquare tests for equal proportions or exact tests between participants who: (a) did and did not indicate awareness about potential fertility loss, and (b) did and did not report discussion of potential fertility loss with their health care providers.
Results: Approximately 46% of the women in our sample (N = 48) reported awareness and 56.3% reported provider discussion of the potential impact of cancer treatment on fertility. Bivariate analyses demonstrated that awareness was significantly higher in women who were diagnosed at age ≤ 45 (p &lt; .05), were nulliparous (p &lt; .01), and/or did not have tubal ligation (p &lt; .001). Provider discussion was more often reported by patients who were diagnosed in stages 2–3 (p &lt; .05) and/or had no children (p &lt; .01).
Nearly half of early onset AA breast cancer patients are unaware and/or report no provider discussion of the potential impact of cancer treatment on fertility. Study results underscore missed clinical opportunities to provide fertility information that may impact long-term quality of life in early onset AA breast cancer patients.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A52.
Abstract A62: Secular trends and disparity of adjuvant hormone therapy use for ductal carcinoma in situ: National Cancer Database, 1998–2007
Authors: Hou Ningqi , Yao Katharine , Winchester David J. , Jaskowiak Nora , Winchester David P. , Huo Dezheng 
Published: June 2012

Abstract
Background: Randomized trials have shown clinical benefit for tamoxifen for patients with ductal carcinoma in situ (DCIS). We surveyed the secular trend and disparities of adjuvant hormone therapy (AHT) utilization for DCIS for the decade following dissemination of these trials.
Methods: We utilized the National Cancer Database, a joint project of the American College of Surgeons and the American Cancer Society to examine secular trends of AHT use among 1,735,160 breast cancer patients diagnosed with breast cancer during 1998–2007. Trends of AHT use were evaluated in DCIS cases, and we stratified the analysis by race/ethnicity, age of diagnosis, and estrogen receptor (ER)/progresterone receptor (PR) status. ER/PR status was available for 2004–2007 only. The general estimating equation (GEE) model with logit link was performed to assess the odds of AHT treatment as a function of the aforementioned variables, clustering on facility to account for within-group correlations.
Results: 258,593 DCIS and 1,360,235 invasive breast cancer cases were included in the analysis. The use of AHT has increased in DCIS patients over time, from 11.7% in 1998, to 23.6% in 1999, and 29.7% in 2007 despite only a 4% increase in the number of DCIS cases over the same time period. Among ER/PR-positive DCIS patients, 37.2% received AHT, whereas only 6.9% ER/PR-negative patients received AHT. Among the ER/PR-positive DCIS patients, we observed a significant disparity of AHT use by race/ethnicity in 2004, but this disparity lost significance in 2006 and 2007; 36.0% white, 31.4% black and 29.9% Hispanic patients used AHT treatment in 2004 (p=0.001), compared to 38.6% white, 37.1% black and 39.5% Hispanic patients in 2007 (p=0.4). Racial disparity also diminished in the GEE model, which removes between-facility differences. AHT use was significantly less in academic/research oriented facilities than in community hospitals (OR=0.74, 95% CI: 0.66–0.83, p&lt;0.0001), and it also varied across facility location. In addition, AHT use varied by age of diagnosis: compared with ER/PR-positive patients at age 50–59, the OR for patients &lt;40 years was 0.58 (95% CI: 0.52–0.65), for patients 40–49 years 0.89 (95% CI: 0.85–0.95), patients 60–69years 0.95 (95% CI:0.90-1.00), patients 70–79 years 0.72 (95% CI: 0.67–0.77), and for patients 80 years or older 0.40 (95% CI: 0.37–0.45). For ER/PR-positive patients 40–69 years old the use of AHT was 39.9%.
Conclusions: AHT utilization nearly doubled from 1998 to 1999 presumably because of the randomized trials but has only slightly increased from 1999–2007. Racial disparities in AHT use among DCIS patients disappeared from 2004 to 2007 but AHT use still varies by patient age, facility type and location.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A62.
Abstract A73: Improving colorectal cancer surveys for New Mexico Hispanics
Authors: Gonzales Melissa , Otero Maria , Hoffman Richard 
Published: June 2012

Abstract
The goal of this research is to produce Spanish- and English-language versions of a colorectal cancer (CRC) risk factor survey that is easily answered by the three main Hispanic sub-populations in New Mexico - US-born and Mexico-born Mexican Americans and native Spanish New Mexicans. We began by conducting an in-depth review of validated surveys covering the domains of demographics, acculturation, personal and family medical history, diet, height and weight, physical activity, smoking and alcohol use. We next evaluated how New Mexico Hispanics interpret and comprehend survey questions and recall information to answer the questions. Our methodology included, in-person field interviewing of self-identified Hispanics age 40 years and older using cognitive-interviewing techniques. All interviews were conducted by a trained, bilingual interviewer. The survey was tested, revised and retested in a new group of participants who met the eligibility requirements. Three results are highlighted here. First, in a novel approach to reconstructing life histories of body mass index (BMI) and physical activity as indicators of energy balance over time, participants reconstructed their body size (height and weight for BMI estimates), work and leisure time physical activity patterns at age 15, 30, 50 years of age and during the previous year. We noted that respondents a) did not easily understand that the activity levels represented a range of physical exertion from none to vigorous, and b) felt they could not select a level if they had not done any of the example activities listed. The instructions were revised to explain the range and the description of the activity levels simplified incorporating the activities our respondents reported performing. Second, the descriptions provided in the gastrointestinal (GI) cancer and CRC screening questions were confusing. Descriptions were simplified for GI cancer risk questions (e.g. familial polypsis, history of polyps) and the CRC screening questions were replaced with modified versions of Behavioral Health Risk Factor Surveillance Survey questions. Last, a memory aide was designed to help the respondents answer the life history questions. The memory aid and revised versions of life history questions, were tested in a second round of field interviews. The memory aid was determined to be an effective method for reconstructing not only body size and activity pattern history, but also lifetime patterns of cigarette smoking and alcohol use. There is a critical need for this CRC survey in our state, where the incidence of CRC among Hispanics is equal to or higher than the incidence in non-Hispanic Whites.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A73.
Abstract A75: Preexisting kidney disorders and risk of renal cell carcinoma: Results from a population-based case-control study of Caucasians and African Americans
Authors: Hofmann Jonathan N. , Schwartz Kendra , Chow Wong-Ho , Ruterbusch Julie J. , Rothman Nathaniel , Wacholder Sholom , Colt Joanne S. , Purdue Mark P. 
Published: June 2012

Abstract
Background: In the United States, the incidence of renal cell carcinoma (RCC) is higher among African Americans (AA) than among Caucasians. However, few studies have investigated potential risk factors that may contribute to racial disparities in RCC incidence. Established risk factors for RCC include smoking, obesity, and hypertension. Beyond these factors the etiology of RCC remains largely unknown, though previous observations suggest that patients with end-stage renal disease on long-term dialysis may be at increased risk of developing RCC.
Methods: We conducted an investigation of RCC risk in relation to pre-existing kidney disorders in a population-based case-control study of AAs and Caucasians in the metropolitan regions of Chicago and Detroit. Personal interviews were conducted to obtain information on history of kidney disorders and other covariates from 1,217 RCC cases (361 AAs and 856 Caucasians) and 1,235 controls (523 AAs and 712 Caucasians). Odds ratios (OR) and 95% confidence intervals (CI) were estimated using sample weighted unconditional logistic regression models adjusted for age, sex, race, level of education, smoking status, body mass index, history of hypertension, family history of cancer, and study center. Analyses stratified by race and time since kidney disease diagnosis were also performed.
Results: A statistically significant increased risk of RCC was observed among subjects who had been previously diagnosed with chronic renal failure (OR 4.7, 95% CI 2.2–10.1) or were on dialysis (OR 18.0, 95% CI 3.6–91.1). Stronger associations were observed among subjects who had renal failure or were on dialysis 10 or more years prior to RCC diagnosis. The association between chronic renal failure and RCC was considerably stronger among AAs than among Caucasians (ORs of 8.7 and 2.0, respectively; P-interaction=0.03). Among AAs, history of kidney stones, kidney cysts, and nephrotic syndrome were all associated with an elevated risk of RCC (OR≥2.0), though these findings were not statistically significant.
Conclusions: The results of this large population-based study suggest that chronic renal failure and dialysis may be important risk factors for RCC development in both AAs and Caucasians. Our findings of differences in risk estimates by race, to our knowledge the first such report, require replication.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A75.
Abstract B40: micro-RNA-128 regulated gene expression in head and neck squamous cell carcinoma
Authors: Hauser Belinda , Hao Yubin , Gu Xinbin , Califano Joseph 
Published: June 2012

Abstract
Purpose: Each year in the United States there are more than 65,000 Americans diagnosed with head and neck cancer and 25,000 die from this disease. Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease with complex molecular abnormalities. African Americans have an incidence approximately twice higher than Caucasian men. The overexpression of BMI1 polycomb ring finger oncogene (BMI-1) and epidermal growth factor receptor (EGFR) in HNSCC cases has been shown to be an indicator of poor prognosis and survival in HNSCC. MicroRNAs are a class of posttranslational regulators of gene expression and have been shown to regulate a number of biological processes. In this study, we investigate that mechanism of microRNA-128 (miR-128) involved the regulation of BMI-1 and EGFR gene expressions in HNSCC.
Methods: We generated stably expressing exogenous miRNA-128 in HNSCC of the Larynx (JHU-22) using lentivirus infection, performed colony formation assays to determine cell growth and proliferation, QRT-PCR to analyze gene expression, and western blot analysis to evaluate protein expression.
Results: The transfected JHU-22miR-128 cell line stably expressed exogenous miR-128 in vitro and in vivo tumor xenografts. Compared with the control vector cells, the cell growth and proliferation decreased significantly in JHU-22miR-128 cells and JHU-22miR-128 tumor xenografts. However, the level of BMI-1proteins was decreased more than EGFR in transfected JHU-22miR-128 cells.
Conclusion: miR-128 is able to significantly inhibit BMI-1protein expression, partially affects EGFR protein expression. miR-128 has a putative target site within the mRNA 3′UTR of Bmi-1 and EGFR. Therefore, miR-128 regulates the proliferative pathway in HNSCC. MiR −128 have potential to serve as a therapeutic approach to specifically target EGFR in HNSCC.
This work was supported in part by grants P20 CA118770 from National Cancer Institute.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):B40.
Abstract B42: A comprehensive resequence-analysis of 250kb region of 8q24 in Africans
Authors: Chung Charles C. , Boland Joseph , Boland Joseph , Chanock Stephen J. , Hsing Ann W. , Yeager Meredith , Yeboah Edward , Biritwum Richard , Tettey Yao , Adjei Andrew , De Marzo Angelo , Netto George 
Published: June 2012

Abstract
The centromeric region flanking the MYC oncogene on 8q24 harbors at least 5 independent loci associated with prostate cancer as well as additional loci associated with distinct cancers of the breast, colon, bladder, and chronic lymphocytic leukemia, all discovered in genome-wide association studies (GWAS). One of the regions has been defined as a 250kb span of 8q24 by linkage disequilibrium (LD) pattern and recombination hotspots (chr8:128050768-128300801, hg19) that contains prostate cancer susceptibility loci rs13254738 and rs16901979, as well as a locus rs2456449 associated with chronic lymphocytic leukemia. Because GWAS identify genetic markers, fine-mapping, based on sequence analysis is necessary to define the optimal variants for biological follow-up. Sequence analysis in distinct populations can provide important insights into the differences in patterns of LD and thus narrow down high interest variants. We have resequenced this region in samples of African ancestry using next-generation technology to comprehensively catalogue variations. Our study sample set included a total of 128 individuals from a population-based study in Ghana. In comparison to the 1000 genome data, we have identified additional variants, which could be important in establishing priorities for future functional work, designed to explain the biological basis of the association signal for both prostate cancer and chronic lymphocytic leukemia.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):B42.
Abstract B47: Identification of health care access factors and psychosocial correlates of cervical cancer screening among Vietnamese American women
Authors: Ma Grace X. , Fang Carolyn Y. , Gao Wanzhen , Tan Yin , Nguyen Joseph An , Feng Ziding 
Published: June 2012

Abstract
Background: Despite the proven survival benefits associated with cervical cancer screening, utilization of the Pap test continues to be suboptimal in certain populations. In particular, Vietnamese American women have one of the lowest rates of screening compared to other ethnic/racial subgroups in the United States (US). A greater understanding of how demographic, psychosocial, and healthcare access factors may be associated with screening behaviors in this population will inform future public health efforts to increase screening and reduce cervical cancer disparities in this population.
Objective: The objective of this study was to characterize demographic, psychosocial, and healthcare access factors that are associated with cervical cancer screening among Vietnamese women.
Methods: Vietnamese women (n=1,525) were recruited into the study from 30 Vietnamese community-based organizations located in Pennsylvania and New Jersey. Participants completed assessments of demographic background, acculturation, and health care access factors in either English or Vietnamese language. In addition, guided by Social Cognitive Theory and the Health Belief Model, participant perceptions of benefits and barriers to screening and self-efficacy in obtaining screening were also assessed.
Results: In this sample of underserved Vietnamese women, the rate of ever having had a Pap test was 53%. To examine factors associated with screening, univariate and multivariate logistical regression analyses were conducted with screening as the outcome variable. Women who were married, were born in the US, or had lived longer in the US were more likely to have obtained screening. As expected, healthcare access variables were associated with screening behavior, such that women who had insurance and had received a physician recommendation for screening were more likely to have obtained screening. With respect to psychosocial beliefs, women who believed that screening can prolong life and who were confident in their ability to get screened were more likely to have undergone screening. In contrast, women's perceived barriers (i.e. a lack of understanding regarding Pap test procedures and embarrassment) were associated with lower rates of screening.
Conclusion: These results highlight the need to address not only health care access issues, but also psychosocial perceptions that may hinder cervical cancer screening behavior in this population. Intervention programs that attend to these various system- and individual-level factors may enhance utilization of cervical cancer screening services among underserved Vietnamese women.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):B47.
Abstract B9: Community strategies for investigating the biology of breast and cervical cancer initiation in African-American women
Authors: Frye Endya L. , Ford Anne , Banks LaMisha , Boyce Xiomara , Robertson Stephanie , Ibarra-Drendall Catherine , Seewaldt Victoria 
Published: June 2012

Abstract
Background: African-American women have the highest overall cancer death rate from breast and cervical cancer and shortest survival of any racial and ethnic group in the United States. These disparities are heightened in the Southern United States. For example, the US breast cancer death rate is 23.0 (per 100,000) for Caucasian women, as compared to 34.3 for African-American women. The North Carolina breast cancer death rate is 27.2 for Caucasian women and 38.0 for African Americans; and in our study area, Durham County, the breast cancer death rate is 27.5 for Caucasians and 42.0 for African-Americans. The causes of these inequalities are complex and interrelated, but arise, at least in part, from disparities in income, education, nutrition, and access to healthcare. For complex historical reasons, African-Americans have had mixed experiences in accessing care and in the quality of care they receive. In addition, distrust has arisen within the African-American community regarding the intents and purposes of health care researchers.
Cutting edge breast imaging technology, prevention, and early detection trials exist at academic that could potentially improve early diagnosis and increase our chance of understanding the complex relationship between disparities, genetics, diet, and the environment in promoting breast cancer. Lack of access, mistrust, and community barriers all play a key role in preventing young African-American women from benefiting from state-of-the-art breast imaging and new strategies for early detection of breast and cervical cancer.
Methods and Results: To address the unacceptably high death rate among young African-American women from breast and cervical cancer, we have used a multi-disciplinary intervention that includes: 1) community Navigators, 2) access to breast and cervical cancer prevention and early detection services through free community clinics, 3) community partnered breast and cervical cancer prevention trials, and 4) opportunities for mentorship and career development. As a result, we have been able to improve access to early detection strategies in a community based setting and have provided mentorship for 27 young Minority scholars to enter medical school and graduate programs. Our community based breast MRI trial for underserved women has performed over 600 breast MRI since 2004. Over 50% of these women entered in this trial are Women-of-Color.
Conclusion: A community based strategy can be highly successful for improving early detection of breast and cervical cancer but only if there is community participation during the initiation of clinical trials and joint community-academic mentorship of young Minority Scholars.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):B9.
Abstract ED03-04: Using epigenetic biomarkers as prognostic and predictive markers in non-small cell lung cancer (NSCLC) and the promise of epigenetic therapy
Authors: Brock Malcolm V. , Juergens Rosalyn A. , Wrangle John , Vendetti Frank P. , Murphy Sara , Zhao Ming , Coleman Barbara , Sebree Rosa , Rodgers Kristen , Hooker Craig M. , Franco Noreli , Lee Beverly , Tsai Salina , Delgado Igor Espinoza , Rudek Michelle A. , Belinsky Steven , Herman James G. , Baylin Stephen B. , Rudin Charles M. 
Published: June 2012

Abstract
Epigenetic gene silencing mediated through aberrant DNA methylation and histone deacetylation is a key contributor to lung carcinogenesis. We have defined the utility of a panel of promoter region DNA methylation markers as a robust potential molecular system for re-staging stage 1 non small cell lung cancer (NSCLC) to molecular stage 3 disease. The significance of our finding is that silencing of these gene markers represents not only prognostic markers, but also these genes may serve as potential targets for a unique new epigenetic approach to re-express the silenced genes. We have just completed a phase 2 trial of epigenetic therapy in NSCLC with documented objective responses. The personalization of this therapy with epigenetic biomarkers may make it especially useful for the medically underserved.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):ED03-04.